Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript May 2, 2024 Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.02505 EPS, expectations were $-1.72. RARE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]
Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) just released its latest first-quarter report and things are not looking...
Explore Ultragenyx Pharmaceutical's Q1 2024 financial performance, strategic milestones, and expert insights from the latest earnings call.